Valeant Pharmaceuticals International Inc.'s IL-17 inhibitor Siliq (brodalumab) may be stuck with a suicidal ideation black box warning and shackled with restricted distribution, but at least the list price in the US is competitive at $3,500 per month for the treatment of psoriasis – the lowest among biologics in the crowded market, according to the company.
Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.